Prospective Electroencephalography Evaluation of Sedation in COVID-19

Goethe University50 enrolled

Overview

Sedation of severe COVID-19 disease are often complicated. We try to find a correlate for this observation by encephalographic studies.

Sedation of critically ill ventilated coronavirus patients, continues to be a challenging issue. Also, neurological symptoms of severe COVID-19 disease have been described frequently. Difficulties in sedation of these patients have been discussed repeatedly. The aim of this study is to investigate whether an encephalographic correlate can be found. Appropriate processed encephalographic techniques have been used for anesthesia monitoring for many years. The aim of our study is to collect unrelated processed and raw EEG data of sedated COVID-19 patients and to investigate the correlation to the necessary sedation.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Conscious Sedation Pathologic Processes Electroencephalogram Acute Respiratory Distress Syndrome Corona Virus Infection

Interventions

Encephalography measurementOTHER

Encephalography measurement and partially aggravated sedation.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: Intubated ventilated patients with SARS-CoV-2 associated acute respiratory distress syndrome and sedation difficulty. Exclusion Criteria: Pre-existing severe cerebral brain damage and dysfunction. For example: previous medial infarction, cerebral hemorrhage, structural epilepsy.

Locations (1)

University Hospital Frankfurt

Frankfurt am Main, Hesse, Germany

Outcomes

Primary Outcomes

Raw data encephalography measurement

Measurement of the brain activity detectable for the examination procedure in the surface encephalogram.

Time frame: From the beginning of the measurement until the end of the examination (10 to 20 minutes).

Processed encephalography measurement

Measurement of detectable algorithm based patient sedation score based on brain activity in the surface encephalogram.

Time frame: From the beginning of the measurement until the end of the examination (10 to 20 minutes).

Secondary Outcomes

Dosage of continuously administered centrally acting alpha2 agonists.

Sedative dosage continuously administered during the measurement interval. \[µg/kg/h\]

Time frame: From 90 minutes before to 10 minutes after encephalographic measurement

Dosage of continuously delivered central GABA receptor active substances.

Sedative dosage continuously administered during the measurement interval. \[mg/kg/h\]

Time frame: From 90 minutes before to 10 minutes after encephalographic measurement

Dosage of continuously delivered central NMDA receptor active substances.

Sedative dosage continuously administered during the measurement interval. \[mg/kg/h\]

Time frame: From 90 minutes before to 10 minutes after encephalographic measurement

Dosage of continuously delivered opioid based analgesia.

Analgetic dosage continuously administered during the measurement interval. \[µg/kg/h\]

Time frame: From 90 minutes before to 10 minutes after encephalographic measurement

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.